W
Wing Yan Au
Researcher at University of Hong Kong
Publications - 20
Citations - 5714
Wing Yan Au is an academic researcher from University of Hong Kong. The author has contributed to research in topics: Peripheral T-cell lymphoma & International Prognostic Index. The author has an hindex of 16, co-authored 16 publications receiving 4900 citations. Previous affiliations of Wing Yan Au include Queen Mary University of London.
Papers
More filters
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project
Wing Yan Au,Dennis D. Weisenburger,Tanin Intragumtornchai,Shigeo Nakamura,Won Seog Kim,Ivy Sng,Julie M. Vose,James O. Armitage,Raymond Liang +8 more
TL;DR: It is concluded that the clinical features and treatment response of extranasal NK/T-cell lymphoma are different from of those of nasal lymphoma, however, the underlying features responsible for these differences remain to be defined.
Journal ArticleDOI
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang,Vladimir Grubor,Cassandra Love,Anjishnu Banerjee,Kristy L. Richards,Piotr A. Mieczkowski,Cherie H. Dunphy,William W.L. Choi,Wing Yan Au,Gopesh Srivastava,Patricia L. Lugar,David A. Rizzieri,Anand S. Lagoo,Leon Bernal-Mizrachi,Karen P. Mann,Christopher R. Flowers,Kikkeri N. Naresh,Andrew M. Evens,Leo I. Gordon,Magdalena Czader,Javed Gill,Eric D. Hsi,Qingquan Liu,Alice Fan,Katherine Walsh,Dereje D. Jima,Lisa L. Smith,Amy J. Johnson,John C. Byrd,Micah A. Luftig,Ting Ni,Jun Zhu,Amy Chadburn,Shawn Levy,David B. Dunson,Sandeep S. Dave +35 more
TL;DR: The patterns of mutation demonstrated a classic long tail distribution with substantial variation of mutated genes from patient to patient and also between published studies, revealing the tremendous genetic heterogeneity that underlies lymphomas and highlights the need for personalized medicine approaches to treating patients.
Journal ArticleDOI
Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
Chee Kin Hui,Winnie W.W. Cheung,Hai Ying Zhang,Wing Yan Au,Yui Hung Yueng,Anskar Y.H. Leung,Nancy Leung,John M. Luk,Albert K. W. Lie,Yok-Lam Kwong,Raymond Liang,George K. K. Lau +11 more
TL;DR: Close surveillance for a 100-fold increase in HBV DNA is recommended for HBsAg-negative patients treated with chemotherapy so that early commencement of antiviral therapy can be initiated before the occurrence of de novo HBV-related hepatitis.
Journal ArticleDOI
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Javeed Iqbal,George E. Wright,Chao Wang,Andreas Rosenwald,Randy D. Gascoyne,Dennis D. Weisenburger,Timothy C. Greiner,Lynette M. Smith,Shuangping Guo,Ryan A. Wilcox,Bin Tean Teh,Soon Thye Lim,Soon Yong Tan,Lisa M. Rimsza,Elaine S. Jaffe,Elias Campo,Antonio Martinez,Jan Delabie,Rita M. Braziel,James R. Cook,Raymond R. Tubbs,German Ott,Eva Geissinger,Philippe Gaulard,Pier Paolo Piccaluga,Stefano Pileri,Wing Yan Au,Shigeo Nakamura,Masao Seto,Françoise Berger,Laurence de Leval,Joseph M. Connors,James O. Armitage,Julie M. Vose,Wing C. Chan,Louis M. Staudt +35 more
TL;DR: Gene-expression profiles, immunohistochemistry, and IDH2 mutation analysis in reclassified cases supported the validity of the reclassification of PTCL-NOS cases, and high expression of several signatures associated with the tumor microenvironment was significantly associated with outcome.